Multi-Center Study Reduces Transplant Risk In AML Patients


January 4, 2010

nccn.com

COLUMBUS (December 5, 2009) – Patients with acute myeloid leukemia (AML) who were treated as part of a multi-center study conducted by the Blood and Marrow Transplant Clinical Trials Network had excellent survival and a low risk of the major complication of transplantation called graft versus host disease. Dr. Steven Devine, Director of the Blood and Marrow Transplant program at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute was the study co-chair and first author of the study.

Devine collaborated with researchers at Dana-Farber Cancer Institute in Boston; Medical College of Wisconsin in Milwaukee, Wis.; Emmes Corporation, Bethesda, MD; City of Hope in Duarte, Calif.; Ireland Cancer Center, University Hospitals of Cleveland Case Medical Center in Cleveland; University of California in San Francisco; Abramson Cancer Center of the University of Pennsylvania, in Philadelphia; Froedtert Memorial Lutheran Hospital East, Medical College of Wisconsin in Milwaukee, Wis. and Pediatrics - BMT, Memorial Sloan-Kettering Cancer Center in New York... read more